Journal article

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Rodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, Richard A Scolyer, Michael T Tetzlaff, Robert Antdbacka, Charlotte Ariyan, Roland Bassett, Brett Carter, Adil Daud, Mark Faries, Leslie A Fecher, Keith T Flaherty, Jeffrey E Gershenwald, Omid Hamid, Angela Hong, John M Kirkwood, Serigne Lo, Kim Margolin, Jane Messina Show all

Lancet Oncol | Published : 2019

Abstract

Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of response and toxicity. Neoadjuvant therapy for regional metastases might improve operability and clinical outcomes over upfront surgery and adjuvant therapy, and has become an established role for drug development and biomarker discovery in other cancers (including locally advanced breast cancer, head and neck squamous cell carcinomas, gastroesophageal cancer, and anal cancer). Patients with clinically detectable stage III melanoma are ideal cand..

View full abstract